Cervical cancer prevention in Indonesia: An updated clinical impact, cost-effectiveness and budget impact analysis
Open Access
- 23 March 2020
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 15 (3), e0230359
- https://doi.org/10.1371/journal.pone.0230359
Abstract
The clinical and economic impact of cervical cancer consistently become a serious burden for all countries, including Indonesia. The implementation of HPV vaccination policy for a big country such as Indonesia requires a strong commitment from several decision-makers. The aim of this study was to provide a comprehensive description on cost-effectiveness and the budget-impact of HPV vaccination policy in Indonesia. A cohort Markov model was used to evaluate the cost and the clinical impact of HPV vaccination for 10 years old girls in Indonesia. The researchers consider two doses of all three available HPV vaccines adjusted with the HPV infection profilewith 95% vaccination coverage to estimate the national cervical cancer incidence and mortality. The Budget impact analysis explores three different scenarios covering (1) Two districts per year expansion, (2) oneprovince per year expansion and (3) achieving the National Immunization Program in 2024. Upon fully vaccinating almost 2.3 million 10-year-old girls, 34,723; 43,414; and 51,522 cervical cancer cases were prevented by Quadrivalent, Bivalent and Nonavalent vaccines, consecutively. Furthermore, the highest (591 cases) and lowest (399 cases) mortality were prevented by Nonavalent and Quadrivalent vaccines, respectively. Most of the vaccines were considerably cost-effective and only the Bivalent vaccine with the GAVI/UNICEF price which will be considered a cost-saving strategy.To provide national coverage of HPV vaccination in Indonesia, the government has to provide an annual budget of about US$49 million and US$22 million using the government contract price and GAVI/UNICEF price, respectively. HPV vaccination shows a cost-effective strategy and the budget required to provide this policy is considerably affordable for Indonesia.Keywords
Funding Information
- Kementerian Riset, Teknologi dan Pendidikan Tinggi (A.11-III/218-S.Pj./LPPM/VI/2018)
This publication has 28 references indexed in Scilit:
- Evaluation of a 5‐year cervical cancer prevention project in Indonesia: Opportunities, issues, and challengesJournal of Obstetrics and Gynaecology Research, 2013
- Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysisThe Lancet Infectious Diseases, 2012
- Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trialThe Lancet Oncology, 2011
- Long-term Impact of Human Papillomavirus Vaccination on Infection Rates, Cervical Abnormalities, and Cancer IncidenceEpidemiology, 2011
- Cost-effectiveness of different human papillomavirus vaccines in SingaporeBMC Public Health, 2011
- Immunogenicity and Safety of Human Papillomavirus-16/18 AS04-Adjuvanted Vaccine Administered According to an Alternative Dosing Schedule Compared With the Standard Dosing Schedule in Healthy Women Aged 15 to 25 YearsThe Pediatric Infectious Disease Journal, 2011
- Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: Modeling of sustained antibody responses☆Gynecologic Oncology, 2009
- Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young womenThe Lancet, 2009
- Macroeconomics and health: investing in health for economic developmentRevista Panamericana de Salud Pública, 2002
- Human Papillomaviruses and Cervical Cancer in Bangkok. II. Risk Factors for in Situ and Invasive Squamous Cell Cervical CarcinomasAmerican Journal of Epidemiology, 2001